| “Perfect” designer chromosome V and behavior of a ring derivative ZX Xie, BZ Li, LA Mitchell, Y Wu, X Qi, Z Jin, B Jia, X Wang, BX Zeng, ... Science 355 (6329), eaaf4704, 2017 | 300 | 2017 |
| Bug mapping and fitness testing of chemically synthesized chromosome X Y Wu, BZ Li, M Zhao, LA Mitchell, ZX Xie, QH Lin, X Wang, WH Xiao, ... Science 355 (6329), eaaf4706, 2017 | 274 | 2017 |
| Synthesis, debugging, and effects of synthetic chromosome consolidation: synVI and beyond LA Mitchell, A Wang, G Stracquadanio, Z Kuang, X Wang, K Yang, ... Science 355 (6329), eaaf4831, 2017 | 255 | 2017 |
| Proteogenomic integration reveals therapeutic targets in breast cancer xenografts K Huang, S Li, P Mertins, S Cao, HP Gunawardena, KV Ruggles, ... Nature communications 8 (1), 14864, 2017 | 165 | 2017 |
| An analysis of the sensitivity of proteogenomic mapping of somatic mutations and novel splicing events in cancer KV Ruggles, Z Tang, X Wang, H Grover, M Askenazi, J Teubl, S Cao, ... Molecular & Cellular Proteomics 15 (3), 1060-1071, 2016 | 138 | 2016 |
| Transcription factor profiling reveals molecular choreography and key regulators of human retrotransposon expression X Sun*, X Wang*, Z Tang, M Grivainis, D Kahler, C Yun, P Mita, D Fenyö, ... Proceedings of the National Academy of Sciences, 201722565, 2018 | 107 | 2018 |
| Mass spectrometry–based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibition in triple-negative breast cancers F Mundt, S Rajput, S Li, KV Ruggles, AD Mooradian, P Mertins, ... Cancer research 78 (10), 2732-2746, 2018 | 62 | 2018 |
| LINE-1 expression in cancer correlates with p53 mutation, copy number alteration, and S phase checkpoint W McKerrow, X Wang, C Mendez-Dorantes, P Mita, S Cao, M Grivainis, ... Proceedings of the National Academy of Sciences 119 (8), e2115999119, 2022 | 59 | 2022 |
| LINE-1 ORF2p expression is nearly imperceptible in human cancers D Ardeljan*, X Wang*, M Oghbaie*, MS Taylor, D Husband, V Deshpande, ... Mobile DNA 11 (1), 1-19, 2020 | 58 | 2020 |
| Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial K Fizazi, M Retz, DP Petrylak, JC Goh, J Perez-Gracia, L Lacombe, ... Journal for immunotherapy of cancer 10 (8), 2022 | 36 | 2022 |
| 520MO Safety and efficacy of nivolumab (NIVO)±ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358 A Oaknin, KN Moore, T Meyer, JL González, L Devriese, A Amin, CD Lao, ... Annals of Oncology 33, S782, 2022 | 30 | 2022 |
| Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner JMH Xuya Wang*, Arshag D. Mooradian*, Petra Erdmann-Gilmore, Qiang Zhang ... Science Signaling 10 (491), 2017 | 29 | 2017 |
| Comprehensive scanning mutagenesis of human retrotransposon LINE-1 identifies motifs essential for function EM Adney, MT Ochmann, S Sil, DM Truong, P Mita, X Wang, DJ Kahler, ... Genetics 213 (4), 1401-1414, 2019 | 21 | 2019 |
| Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial A Oaknin, K Moore, T Meyer, JLP González, LA Devriese, A Amin, CD Lao, ... The Lancet Oncology 25 (5), 588-602, 2024 | 20 | 2024 |
| CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO)+ rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC). RK Pachynski, M Retz, JC Goh, M Burotto, G Gravis, D Castellano, ... Journal of Clinical Oncology 39 (15_suppl), 5044-5044, 2021 | 17 | 2021 |
| Efficacy and Safety of Nivolumab in Combination With Docetaxel in Men With Metastatic Castration-Resistant Prostate Cancer in CheckMate 9KD K Fizazi, PG Mella, D Castellano, JN Minatta, AR Kalebasty, D Shaffer, ... European Society for Medical Oncology Congress 2019, 2019 | 15 | 2019 |
| A first step towards a clinical decision support system for post-traumatic stress disorders S Ma, IR Galatzer-Levy, X Wang, D Fenyö, AY Shalev AMIA Annual Symposium Proceedings 2016, 837, 2017 | 12 | 2017 |
| Immune checkpoint blockade outcome in small-cell lung cancer and its relationship with retinoblastoma mutation status and function A Dowlati, A Abbas, T Chan, B Henick, X Wang, P Doshi, P Fu, J Patel, ... JCO Precision Oncology 6, e2200257, 2022 | 9 | 2022 |
| The largest SWI/SNF polyglutamine domain is a pH sensor JI Gutiérrez, G Brittingham, X Wang, D Fenyö, LJ Holt bioRxiv, 165043, 2017 | 9 | 2017 |
| Physiological basis of copper tolerance of Saccharomyces cerevisiae nonsense‐mediated mRNA decay mutants X Wang, O Okonkwo, BW Kebaara Yeast 30 (5), 179-190, 2013 | 9 | 2013 |
David FenyoProfessor, New York UniversityVerified email at FenyoLab.org
